TScan Therapeutics Business Summary

TScan Therapeutics, Inc. (TCRX) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic research collaborations and licensing agreements, most notably a multi-year partnership with Amgen to identify T-cell targets for Crohn’s disease. The company’s business is segmented into two primary therapeutic areas: hematologic malignancies and solid tumors. Its lead candidate, TSC-101, is transitioning into a pivotal trial in Q2 2026 for the treatment of AML and MDS patients post-transplant, while its solid tumor segment is pivoting toward in vivo-engineered TCR-T therapies. TScan competes directly with other T-cell receptor and cell therapy developers such as Fate Therapeutics, Achilles Therapeutics, and T-Knife Therapeutics. Within this landscape, TScan distinguishes itself through its proprietary TargetScan and ReceptorScan platforms, which enable the discovery of naturally occurring TCRs from "exceptional responders" to immunotherapy, positioning the firm as a leader in high-throughput antigen identification. The leadership team is anchored by CEO Gavin MacBeath, Ph.D., who previously served as the company’s CSO and held faculty positions at Harvard University after co-founding Merrimack Pharmaceuticals. The executive suite includes CFO Jason Amello, formerly of Akebia Therapeutics, and CMO Chrystal Louis, M.D., who brings extensive oncology experience from Bristol Myers Squibb. The company was co-founded by Lea Hachigian and Stephen Elledge, a renowned geneticist from Harvard Medical School. TScan is backed by a sophisticated roster of institutional investors, including Novartis, Google Ventures (GV), and Baker Bros. Advisors LP. The Board of Directors is chaired by Stephen Biggar, M.D., Ph.D., a partner at Baker Bros., and includes industry veterans such as Garry Nicholson, the former President of Pfizer Oncology.